Yusuf Hamied
Angel Investor
Mumbai, India
Yusuf Hamied is a Cambridge-educated Chemist and the Non-Executive Chairman of the Board of Directors at Cipla, a large generic pharmaceuticals company founded in 1935 by his father, Khwaja Abdul Hamied. Yusuf became a global celebrity for his role in defying Western multinational pharmaceutical companies in order to provide generic AIDS treatmentsand other drugs to treat poor people in the developing world. After completing his doctorate in 1960, Yusuf joined the family company and vowed to break the dominance of foreign multinationals over the Indian pharmaceutical market by developing cheap generic drugs. Yusuf helped persuade the Indian government to change Indian patent law in 1972, permitting medicines to be copied even if they were under international patent, as long as the process was not the same. The law transformed the Indian pharmaceutical industry, enabling his and other companies to grow by manufacturing generic drugs. In 2001 Yusuf convulsed the global healthcare industry by promising and then delivering a triple drug cocktail, Triomune, that helped fight against HIV and AIDS at prices far lower than those available internationally. Yusuf discusses his subsequent anger when, in 2005, the Indian government brought its patent laws in line with those of the developed world, prohibiting the copying of drugs patented after 1995 without a license and his resentment that he had thereafter “to go with a begging bowl to the multinationals” for licenses. This interview provides not only a personal perspective on how India’s third largest pharmaceutical firm was created, but contributes to the broad debates on the costs and benefits of intellectual property laws, particularly their impact on people who are denied life-saving drugs by their inability to pay for them. Working for Cipla as Managing Director for nearly 52 years, Yusuf was also the 28th richest Indian during one time. ‘CNN-IBN Indian of the year’ and one among the ’25 greatest global living legends’ were the titles that Yusuf won for his reign in the pharma world majorly for making medicines affordable to the poor. Yusuf was awarded with the civil honorary Padma Bhushan from then president APJ Abdul Kalam in the year 2005 for his fight against AIDS, which he often said was going to be as damaging to the society as a massive earthquake would be, if ignored. Yusuf earned his Bachelor's degree (1956), Master's degree (1957) and Ph.D. (1960) in Chemistry from University of Cambridge.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Yusuf Hamied invests in
Stages Yusuf Hamied invests in
Countries Yusuf Hamied invests in
Investment Focus
Industry
- Medical 1 (100%)
- Medical Device 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
1inhaler
|
1inhaler operates as a developer of drug delivery device. | $2.5M / Seed / Nov 27, 2023 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Yusuf Hamied invest in?
Yusuf Hamied invests primarily in Medical and Medical Device startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Yusuf Hamied last invest?
The most recent investment recorded for Yusuf Hamied closed in Nov 2023. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
